BNTC vs. CALT, AUPH, BGM, NAGE, AMPH, DYN, ABCL, PAHC, WVE, and ELVN
Should you be buying Benitec Biopharma stock or one of its competitors? The main competitors of Benitec Biopharma include Calliditas Therapeutics AB (publ) (CALT), Aurinia Pharmaceuticals (AUPH), BGM Group (BGM), Niagen Bioscience (NAGE), Amphastar Pharmaceuticals (AMPH), Dyne Therapeutics (DYN), AbCellera Biologics (ABCL), Phibro Animal Health (PAHC), WAVE Life Sciences (WVE), and Enliven Therapeutics (ELVN). These companies are all part of the "pharmaceutical products" industry.
Benitec Biopharma vs. Its Competitors
Benitec Biopharma (NASDAQ:BNTC) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.
In the previous week, Benitec Biopharma had 1 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 1 mentions for Benitec Biopharma and 0 mentions for Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.00 beat Benitec Biopharma's score of -0.27 indicating that Calliditas Therapeutics AB (publ) is being referred to more favorably in the news media.
Benitec Biopharma has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500.
Benitec Biopharma has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Benitec Biopharma's return on equity of -38.26% beat Calliditas Therapeutics AB (publ)'s return on equity.
Benitec Biopharma has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks.
52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 1.3% of Benitec Biopharma shares are held by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Benitec Biopharma currently has a consensus price target of $23.83, suggesting a potential upside of 81.38%. Given Benitec Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Benitec Biopharma is more favorable than Calliditas Therapeutics AB (publ).
Summary
Benitec Biopharma beats Calliditas Therapeutics AB (publ) on 12 of the 17 factors compared between the two stocks.
Get Benitec Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BNTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Benitec Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:BNTC) was last updated on 7/3/2025 by MarketBeat.com Staff
Free BNTC Stock Alerts